MAPT and Alzheimer disease: A number of approaches for quantifying amyloid-beta plaques and tau neurofibrillary tangles (NFTs) in AD show high accuracy when compared to manual counts [71, 81, 84, 90, 99]; others have also been developed to quantify TDP-43 pathology [56].